The company
Prime Medicine, Inc.
PRME · Nasdaq
PRME stood above a rising 150-day average in 9 of the last 52 weekly readings, and has been out of that trend for the last 38 weeks. It is 17.0% above that average now. Biotechnology: 18% of its 561 stocks in an uptrend (−14 points in four weeks); Health Care: 28% (−9 points in four weeks).
Statistics
- Rotation
- Above a falling average
- Weeks in an uptrend
- out for 38
- Industry in uptrend
- 18% -14 in 4 wk
- Insider buys, 12 months
- $0
- Insider sales, 12 months
- $0
- Officials’ trades on record
- 0
- Institutions holding
- 177 (-3)
In the rotation
Each square a week: lit when it closed above a rising 150-day average. 9 of 52 weeks.
Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.
Money in and out
Open-market buys above the line and sales below, in dollars.
Congress and officials
No member of Congress or official has disclosed a trade in it.
Insiders
No open-market buy or sale by its insiders on record.
Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.
Institutions
Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.
| Manager | Shares | Change |
|---|---|---|
| Alphabet Inc.unchanged · filed 7 Aug 2026 | 16,562,498$61.1M | 00.0% |
| BlackRock, Inc.added · filed 7 Aug 2026 | 9,602,041$35.4M | +1,100,333+12.9% |
| ARK Investment Management LLCadded · filed 14 Aug 2026 | 8,348,746$30.8M | +2,101,919+33.6% |
| STATE STREET CORPadded · filed 7 Aug 2026 | 7,576,460$28.0M | +1,231,335+19.4% |
| VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026 | 4,522,640$16.7M | +48,478+1.1% |
| Balyasny Asset Management L.P.reduced · filed 14 Aug 2026 | 3,969,082$14.6M | -154,283−3.7% |
| GOLDMAN SACHS GROUP INCadded · filed 14 Aug 2026 | 3,430,518$12.7M | +2,460,093+253.5% |
| Casdin Capital, LLCunchanged · filed 14 Aug 2026 | 3,167,175$11.7M | 00.0% |
| Woodline Partners LPadded · filed 14 Aug 2026 | 3,003,904$11.1M | +5910.0% |
| UBS Group AGreduced · filed 13 Aug 2026 | 2,794,689$10.3M | -93,729−3.2% |
Everyone who traded it
Same industry
Government contracts
No federal award is tied to it.
From its SEC filings
Analyst forecasts
No analyst forecasts yet.